FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Solarvest BioEnergy Inc. ("Solarvest" or the "Company")
439 Helmcken Street,
Vancouver, B.C.
V6B 2E6

2. Date of Material Change

January 19, 2015

3. News Release

News releases with respect to this material change were disseminated on January 5, 2015 and January 19, 2015 via Marketwired.

4. Summary of Material Change

Solarvest has completed its previously announced debt settlement with Cawkell Brodie LLP ("Cawkell Brodie").

5. Full Description of Material Change

On January 19, 2015, Solarvest completed a transaction to settle the sum of $100,000 as recorded in its financial statements, which was due to Cawkell Brodie in connection with legal services rendered during fiscal 2009 and 2010. Pursuant to a letter agreement the total debt was settled through the issuance of 285,714 common shares at a deemed price of $0.35 per share.

This transaction involved certain related parties. Specifically, Kenneth A. Cawkell is a partner of Cawkell Brodie and is also a director, chairman and secretary of Solarvest. The transaction is exempt from the valuation and shareholder approval requirements of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"), since neither the fair market value of the shares issued, nor the consideration paid for the transaction, totalled more than 25% of the market capitalization of the Company before giving effect to the transaction. Specifically, this transaction is exempt from shareholder approval in accordance with section 5.7(1)(a) of MI 61-101 and no formal valuation has been conducted for this transaction in accordance with section 5.5(a) of MI 61-101. The price has been set at $0.35 based upon Solarvest's trading price and other recent transactions completed by the Company.

Mr. Cawkell declared his interest in the transaction to the Board and abstained from voting on the resolution approving the shares for debt. The details of this transaction were approved by the Board of Directors on January 5, 2015.

The common shares issuable pursuant to the purchase agreement will be subject to resale restrictions for a period of four months from the closing date under applicable securities legislation.

For further details please see the attached news release.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

7. Omitted Information

No information has been omitted from this report on the basis that it is confidential information.

8. Executive Officer

Kenneth A. Cawkell, Secretary
Tel: (604) 684 3323

9. Date of Report

January 19, 2015

Solarvest BioEnergy
Harvesting Energy from the Sun

FOR IMMEDIATE RELEASE TSX-V: SVS

SOLARVEST COMPLETES $100,000 DEBT SETTLEMENT

Vancouver, BC, January 19, 2015 – SOLARVEST BIOENERGY INC. (TSX-V:SVS) ("Solarvest"), announces that it has settled the sum of $100,000 as recorded in its financial statements, which was due to Cawkell Brodie LLP in connection with legal services rendered during fiscal 2009 and 2010, by way of a shares for debt. Pursuant to a letter agreement the total debt was settled through the issuance of 285,714 common shares at a deemed price of $0.35 per share.

This transaction involved certain related parties and is exempt from shareholder approval accordance with MI 61-101 (Protection of Minority Security Holders in Special Transactions). Specifically, Kenneth A. Cawkell is a partner of Cawkell Brodie LLP and is also a director, chairman and secretary of Solarvest.

The common shares issuable pursuant to the purchase agreement will be subject to resale restrictions for a period of four months from the closing date under applicable securities legislation.

About Solarvest:
Solarvest is an algae technology company that owns numerous key patents and whose algal-based production platform provides it with an extremely flexible production system. The Company's wholly owned subsidiary, Solarvest PEI, has developed a patented (pending) process to produce the world's first organic Omega-3 using algae, to help meet the 13 billion dollar global Omega-3 market. The Solarvest system utilizes a natural process growing the algae under closely controlled conditions ensuring that the health product(s) produced have none of the environmental contaminants found in our oceans. Organic certification provides assurance that the product(s) is GMO free, sustainable, produced without chemicals and, being algae, supports vegetarian and vegan diets. Solarvest's licensed Organic Omega-3 products will offer the consumer a healthy and sustainable product choice.

For further information contact: Gerri Greenham, Chief Executive Officer
Tel: 416 420 0947 Email: ggreenham@solarvest.ca